BK-508 (Dual-specific Antibody)
Advanced Solid Tumors
Phase I/IIRecruiting
Key Facts
About Sichuan Biokin Pharmaceutical
Sichuan Biokin Pharmaceutical's mission is to develop and commercialize high-quality, accessible biologic medicines for patients in China and worldwide. The company has achieved significant success by establishing itself as a dominant player in the Chinese biologics market, evidenced by its substantial market capitalization and integrated capabilities from discovery through commercialization. Its core strategy employs a dual-track approach: generating stable cash flow from biosimilars to fund the research and development of novel therapeutic antibodies in high-value therapeutic areas.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |
| BI-1808 | BioInvent International | Phase 1/2a |
| GIGA-564 | GigaGen | Phase 1 |
| Venadaparib (IDX-1197) | Idience | Phase 1a |
| VET3-TGI | KaliVir Immunotherapeutics | Phase 1 |
| IT-141 (Etoposide IVECT™) | Intezyne | Phase 1 |
| NC318 | NextCure | Phase 1/2 |
| VisAcT (18F-AraG) Imaging in Solid Tumors | CellSight Technologies | Phase 1/2 |